CFSAN Supplement "Disease Claims" Enforcement Authority Spelled Out
This article was originally published in The Tan Sheet
Executive Summary
FDA's Center for Food Safety & Applied Nutrition has lead responsibility for issuing warning letter drug charges for dietary supplements bearing "disease claims," under an April 6 intercenter agreement with the Center for Drug Evaluation & Research.
You may also be interested in...
Cholestin Red Yeast Rice Shipments Halted Pending FDA Talks
Pharmanex suspended U.S. shipments of Cholestin April 2 following a federal court decision affirming FDA's determination that the red yeast rice product is a drug, not a dietary supplement.
Dietary Supplement Enforcement Procedure Streamlining Planned By CFSAN
Consolidating FDA's enforcement process with regard to inappropriate dietary supplement claims is one of the Center for Food Safety & Applied Nutrition's "A-list" goals for 2000.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC